JPWO2021050857A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021050857A5
JPWO2021050857A5 JP2022516402A JP2022516402A JPWO2021050857A5 JP WO2021050857 A5 JPWO2021050857 A5 JP WO2021050857A5 JP 2022516402 A JP2022516402 A JP 2022516402A JP 2022516402 A JP2022516402 A JP 2022516402A JP WO2021050857 A5 JPWO2021050857 A5 JP WO2021050857A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547718A (ja
JP2022547718A5 (https=
JP7796008B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050380 external-priority patent/WO2021050857A1/en
Publication of JP2022547718A publication Critical patent/JP2022547718A/ja
Publication of JP2022547718A5 publication Critical patent/JP2022547718A5/ja
Publication of JPWO2021050857A5 publication Critical patent/JPWO2021050857A5/ja
Priority to JP2025135892A priority Critical patent/JP2025183231A/ja
Application granted granted Critical
Publication of JP7796008B2 publication Critical patent/JP7796008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516402A 2019-09-13 2020-09-11 抗cd371抗体およびその使用 Active JP7796008B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135892A JP2025183231A (ja) 2019-09-13 2025-08-18 抗cd371抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900118P 2019-09-13 2019-09-13
US62/900,118 2019-09-13
US201962936913P 2019-11-18 2019-11-18
US62/936,913 2019-11-18
PCT/US2020/050380 WO2021050857A1 (en) 2019-09-13 2020-09-11 Anti-cd371 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135892A Division JP2025183231A (ja) 2019-09-13 2025-08-18 抗cd371抗体およびその使用

Publications (4)

Publication Number Publication Date
JP2022547718A JP2022547718A (ja) 2022-11-15
JP2022547718A5 JP2022547718A5 (https=) 2025-02-06
JPWO2021050857A5 true JPWO2021050857A5 (https=) 2025-02-06
JP7796008B2 JP7796008B2 (ja) 2026-01-08

Family

ID=74866534

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516402A Active JP7796008B2 (ja) 2019-09-13 2020-09-11 抗cd371抗体およびその使用
JP2025135892A Pending JP2025183231A (ja) 2019-09-13 2025-08-18 抗cd371抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135892A Pending JP2025183231A (ja) 2019-09-13 2025-08-18 抗cd371抗体およびその使用

Country Status (11)

Country Link
US (1) US20220195064A1 (https=)
EP (1) EP4028422A4 (https=)
JP (2) JP7796008B2 (https=)
KR (1) KR20220069961A (https=)
CN (1) CN114641503B (https=)
AU (1) AU2020346886A1 (https=)
BR (1) BR112022004603A2 (https=)
CA (1) CA3154387A1 (https=)
IL (1) IL291280A (https=)
MX (1) MX2022003074A (https=)
WO (1) WO2021050857A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002392A1 (en) * 2021-07-20 2023-01-26 Abl Bio Inc. Anti-cll-1/anti-cd3 bispecific antibodies and uses thereof
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
WO2025193609A1 (en) 2024-03-11 2025-09-18 Caribou Biosciences, Inc. Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543635A (en) * 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
ES2650224T3 (es) * 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP3453723B1 (en) * 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
WO2016069549A1 (en) * 2014-10-28 2016-05-06 Albert Einstein College Of Medicine, Inc. Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins
WO2015174978A1 (en) * 2014-05-15 2015-11-19 R-Pharm Overseas, Inc. Antibodies against human receptor integrin alpha-4
EP3221351B1 (en) * 2014-11-19 2024-11-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
SI3115376T1 (sl) * 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
CN108290955A (zh) * 2015-11-24 2018-07-17 塞勒兰特治疗公司 人源化抗-cll-1抗体
RU2019121662A (ru) * 2016-12-16 2021-01-18 Мерк Патент Гмбх Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита
CA3154389A1 (en) * 2019-09-13 2021-03-18 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd371 and uses thereof
KR20240087985A (ko) * 2022-12-13 2024-06-20 엘지디스플레이 주식회사 표시장치

Similar Documents

Publication Publication Date Title
JP2018500014A5 (https=)
US20210024635A1 (en) Anti-wt1/hla-specific antibodies
RU2766094C2 (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP5723279B2 (ja) 抗cxcr4抗体および癌治療のためのそれらの使用
JP2020504723A5 (https=)
JP2021527431A5 (https=)
JP2020501531A5 (https=)
JP2021531005A5 (https=)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2018504890A5 (https=)
RU2006103854A (ru) Антитела к рецептору инсулиноподобного фактора роста i и их применение
JP2017529838A5 (https=)
JP2020513791A5 (https=)
JP2017535257A5 (https=)
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
JP2021524478A5 (https=)
JP2010509931A (ja) 新規抗増殖性化合物
JP2010501164A5 (https=)
JP2015503909A5 (https=)
JP2017537082A5 (https=)
JP2019534705A5 (https=)
JP2021520201A5 (https=)
JP2019512207A5 (https=)
US20250042980A1 (en) Complement factor h antibodies
WO2015105973A1 (en) ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF